Abstract
Somatostatin and its analogue, octreotide, produce dramatic decreases in splanchnic arterial blood flow and portal venous pressure while preserving cardiac output and systemic blood pressure. A limited number of prospective randomized clinical trials of somatostatin and octreotide have noted superiority to placebo and equivalence to vasopressin in control of variceal hemorrhage. Moreover, several studies (Saari et al., Kravetz et al., McKee et al.) have reported a significant decrease in morbid side effects when somatostatin or octreotide is used to control variceal bleed. In addition, McKee et al. noted a significant reduction in mortality when octreotide was compared to balloon tamponade therapy for variceal hemorrhage. Somatostatin and octreotide are particularly advantageous in controlling vigorous variceal hemorrhage in hemodynamically unstable patients. This control often enables other effective therapy, endoscopic sclerotherapy and surgical (or radiologic) shunting, to be safely performed.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
